Longevity Research: mTOR, AMPK, Sirtuins, Rapamycin, and NMN

Rapamycin Extended Mouse Lifespan by 14% — Starting at Age 60 in Human Terms

When the Interventions Testing Program (ITP) — a rigorous multi-site NIA-funded program — gave rapamycin to genetically heterogeneous mice starting at 600 days of age (roughly equivalent to 60 human years), median lifespan increased by 14% in females and 9% in males. This was not a marginal result. It was the first drug shown to extend lifespan in a mammal when initiated in mid-to-late life. The ITP result, published in Nature in 2009 by Harrison et al., launched a new era in longevity pharmacology. The mechanism: rapamycin inhibits mTOR complex 1 (mTORC1), the master growth and aging regulator.

Three Pathways, One Goal

Aging biology now recognizes three interconnected nutrient-sensing pathways as primary regulators of lifespan across organisms from yeast to mammals. Understanding their relationships clarifies why the same lifestyle interventions — caloric restriction, fasting, exercise — activate multiple longevity mechanisms simultaneously.

These pathways are not independent. AMPK activates SIRT1 (by increasing NAD+); SIRT1 inhibits mTORC1 indirectly. Caloric restriction engages all three simultaneously, which may explain why it remains the most consistently effective longevity intervention across species.

CALERIE 2: Human Caloric Restriction at 14.3%

The Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy Phase 2 (CALERIE 2) trial randomized 218 healthy, non-obese adults aged 21–50 to 25% caloric restriction for 2 years. Actual restriction achieved was 11.9% on average. Published in The Lancet Diabetes & Endocrinology (2015, Lefevre et al.), the trial found statistically significant improvements in cardiometabolic risk factors. A 2023 follow-up analysis (Das et al., Nature Aging) found CALERIE 2 participants showed a 14.3% slowing of biological aging pace as measured by the DunedinPACE epigenetic clock — the first randomized evidence that caloric restriction slows biological aging rate in healthy humans.

NAD+ Decline and Sirtuin Dysfunction

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential for mitochondrial energy metabolism and the required substrate for sirtuin activity. NAD+ levels decline with age — by approximately 50% between ages 40 and 60 in human tissues. This decline limits sirtuin activity (sirtuins consume NAD+ to deacetylate target proteins) and impairs mitochondrial function. The hypothesis driving the NMN and NR supplement industry: supplying NAD+ precursors restores NAD+ levels and thereby activates sirtuin-mediated longevity pathways.

• NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) both raise NAD+ levels in blood and tissues in human trials.
• A 2021 RCT by Yoshino et al. in Science found 250 mg/day NMN for 10 weeks increased skeletal muscle NAD+ metabolome in postmenopausal women and improved muscle insulin sensitivity — but only in a subgroup with lower baseline NAD+ levels.
• No human RCT has yet demonstrated that NAD+ precursor supplementation extends lifespan or healthspan at the organism level; all longevity effects remain inferred from mechanism and animal data.

Rapamycin: Promise and Toxicity

Rapamycin (sirolimus) was approved by the FDA in 1999 as an immunosuppressant for transplant patients. At transplant doses (several mg/day), it causes serious side effects including immunosuppression, impaired wound healing, hyperlipidemia, and glucose intolerance. The longevity research community, led by figures including Matt Kaeberlein at the University of Washington, has explored low-dose intermittent rapamycin (typically 2–6 mg/week) as a strategy to capture mTOR inhibition benefits while limiting side effects. Dog Aging Project data, published in 2016, found intermittent rapamycin improved cardiac function in middle-aged dogs. Human data is largely limited to case reports, self-experimenter reports (including longevity physicians like Peter Attia who have discussed personal use), and small observational studies. No large randomized trial has yet established safety and efficacy of longevity-dose rapamycin in healthy humans.

Senolytics: Clearing Zombie Cells

Cellular senescence — the state in which cells stop dividing but resist apoptosis and secrete pro-inflammatory signals (the SASP: senescence-associated secretory phenotype) — accumulates with age and drives tissue dysfunction. Senolytic drugs selectively clear senescent cells. The best-studied combination is dasatinib (a cancer drug) plus quercetin (a flavonoid). A 2019 pilot human trial (Kirkland et al., EBioMedicine) in patients with idiopathic pulmonary fibrosis found dasatinib + quercetin improved physical function over 3 weeks. The Mayo Clinic has ongoing trials in multiple age-related conditions.

• The TAME (Targeting Aging with Metformin) trial, funded by the American Federation for Aging Research, is the first FDA-approved trial to test an anti-aging intervention in 3,000 older adults — results expected by 2028.
• Epigenetic clocks (Horvath, DunedinPACE, GrimAge) are becoming standard outcome measures in longevity trials as they provide continuous biological aging rate data rather than waiting decades for mortality endpoints.
• No supplement, drug, or dietary pattern has been proven to extend human lifespan in a controlled trial. The mechanistic evidence is compelling; the human proof remains pending.

This article is for informational purposes only. Consult a qualified healthcare professional.